Narcolepsy
Conditions
Keywords
Pediatric Narcolepsy
Brief summary
This study is to evaluate the pharmacokinetics, pharmacodynamics, and safety of single and multiple doses of armodafinil (50, 100, and 150 mg/day) in children and adolescents with excessive sleepiness associated with narcolepsy.
Interventions
DRUGArmodafinil
The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent is obtained from each patient's parent or legal guardian and written assent is obtained from each patient. * The patient is a male or female 6 through 17 years of age with a body mass index (BMI) equal to or greater than 10th percentile for age and gender, inclusive. * The patient has a diagnosis of narcolepsy with cataplexy or narcolepsy without cataplexy according to the criteria established by the International Classification of Sleep Disorders (ICSD)-2 for narcolepsy.
Exclusion criteria
* The patient has any clinically significant uncontrolled medical condition (treated or untreated) other than narcolepsy. * The patient has a clinically significant deviation from normal in ECG, physical examination or vital sign findings, as determined by the investigator or medical monitor. * The patient is pregnant or lactating. (Any patient becoming pregnant during the study will be withdrawn from the study) * The patient has any history of seizures, including febrile seizures, or a family history of seizures (in parents or siblings) which is not a consequence of trauma, stroke, or metabolic disturbance. * The patient has a history of head trauma associated with loss of consciousness. * The patient has current suicidal ideation, a history of a suicidal ideation, or a history of a suicide attempt. * The patient has a history of major depressive disorder, bipolar disorder, other significant mood disorders, schizophrenia and other psychotic disorders, eating disorders, or has a family history of suicide. * The patient has left ventricular hypertrophy or the patient has mitral valve prolapse and has experienced mitral valve prolapse syndrome. * The patient has received any investigational drug within 30 days or 5 half-lives (whichever is longer) before the 1st dose of study drug, or in the case of a new chemical entity, 3 months or 5 half-lives (whichever is longer) before the 1st dose of study drug. * The patient has used any monoamine oxidase inhibitors (MAOIs) or stimulants within 14 days or 5 half-lives (whichever is longer) of the baseline visit. * The patient has used modafinil or armodafinil within 4 weeks of the baseline visit. * The patient has used an inducer of CYP3A4/5 within 28 days prior to study drug administration. * The patient has used an inhibitor of CYP3A4/5 within 14 days or 5 half lives (whichever is longer) prior to study drug administration. * The patient has a known sensitivity or idiosyncratic reaction to any compound present in modafinil or armodafinil, their related compounds, or to any metabolites or compound listed as being present in these medications. * The patient has a history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction, including multiple allergies or drug reactions * Other criteria apply, please contact the investigator for additional information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steady-state accumulation ratio | Day 42 + up to 72 hours after administration |
| AUC 0-t | Day 42 + up to 72 hours after administration |
| Observed accumulation ratio | Day 42 + up to 72 hours after administration |
| Maximum observed plasma drug concentration (Cmax) by inspection | Day 1 + up to 72 hours after administration |
| Time to maximum observed plasma drug concentration (tmax) by inspection | Day 1 + up to 72 hours after administration |
| Area under the plasma drug concentration by time curve from time 0 to infinity | Day 1 + up to 72 hours after administration |
| Area under the plasma drug concentration by time curve from time 0 to the time of the last measurable drug concentration | Day 1 + up to 72 hours after administration |
| Terminal half-life | Day 1 + up to 72 hours after administration |
| Terminal elimination rate constant | Day 1 + up to 72 hours after administration |
| Apparent total plasma clearance | Day 1 + up to 72 hours after administration |
| Apparent volume of distribution | Day 1 + up to 72 hours after administration |
| Predicted accumulation ratio | Day 1 + up to 72 hours after administration |
| Maximum observed plasma drug concentration (Cmax) | Day 42 + up to 72 hours after administration |
| Time to maximum observed plasma drug concentration | Day 42 + up to 72 hours after administration |
| AUC over 1 dosing interval | Day 42 + up to 72 hours after administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Global Impression of Change (CGI-C) | Day 1 | An assessment by the investigator of change in the patient's severity of excessive sleepiness during the course of the study. The clinician will ask the guardian to assess the child's home behavior over the past week. |
| Mean sleep latency | 2 Days (Baseline + Day 1) | An objective assessment of sleepiness that measures the likelihood of falling asleep. The test consists of multiple naps performed on the day before study drug administration in period 1 and on the day of study drug administration in period 1. For each nap, sleep latency will be measured as the elapsed time from lights-out to the first epoch scored as sleep. Mean sleep latency is calculated for each day as the average of the sleep latencies from each nap on that day. |
Countries
Finland, United States
Outcome results
None listed